Please assess the completion status of the following clinical trial:

Trial Title: Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Recurrent malignant glioma with radiographic progression~* No more than three prior therapies.~* Male or female patients \>=18 years old~* KPS \>=60.~* Ability to provide written informed consent or consent obtained from responsible healthcare proxy.~* Contrast-enhanced MRI within 2 weeks of enrollment.~* Life expectancy \>= 8 weeks~* Neutrophils \>1500/mm3~* Platelets \> 100,000/mm3L~* Hemoglobin \>=9 g/dL~* AST/SGOT and ALT/SGPT \<= 2.5 x upper limit of normal (ULN) or \< 5.0 x ULN if the transaminase elevation is due to disease involvement~* Serum bilirubin \<= 1.5 x ULN~* Serum creatinine \<= 1.5 x ULN or 24-hour creatinine clearance \>= 50 ml/min~* Total serum calcium or ionized calcium WNL~* Serum potassium WNL~* Serum sodium WNL~* Serum albumin \>= LLN or 3g/dl~* Elevated Alkaline Phosphatase due to bone metastasis can be enrolled~* Baseline MUGA or ECHO must demonstrate LVEF \>= the LLN~* TSH and free T4 WNL (patients may be on thyroid hormone replacement)~* Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days of the first administration of study treatment and must be willing to use two methods of contraception one of them being a barrier method during the study and for 3 months after last study drug administration.~* No concurrent antitumor therapy.~* No enzyme-inducing antiepileptic drugs.~* No significant comorbidities~* Patients must have recovered from toxic effects of prior therapy.~Exclusion criteria~* Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer~* Valproic acid for any medical condition during the study or within 5 days prior to first LBH589 treatment~* Impaired cardiac function including:~* Screening ECG with a QTc \> 450 msec~* Congenital long QT syndrome~* History of sustained ventricular tachycardia~* History of ventricular fibrillation or torsades de pointes~* Bradycardia \< 50 beats per minute. Patients with a pacemaker and heart rate \> = 50 beats per minute are eligible.~* Myocardial infarction or unstable angina within 6 months~* Congestive heart failure (NYHA class III or IV)~* RBBB and LAH (bifascicular block)~* Uncontrolled hypertension~* Concomitant use of drugs with a risk of causing torsades de pointes Concomitant use of CYP3A4 inhibitors~* Patients with unresolved diarrhea~* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter absorption of LBH589~* Concurrent severe and/or uncontrolled medical conditions~* Chemotherapy, any investigational drug or major surgery \< 4 weeks prior to starting study drug or have not recovered from side effects of such therapy.~* Concomitant use of any anti-cancer therapy or radiation therapy.~* Women who are pregnant or breast feeding or women of childbearing potential (WOCBP) not willing to use a double barrier method of contraception during the study and 3 months after the end of treatment. One of these methods of contraception must be a barrier method.~* Male patients whose sexual partners are WOCBP not using a double method of contraception during the study and 3 months after the end of treatment. One of these methods must be a condom~* History of another primary malignancy within 5 years other than curatively treated CIS of the cervix, or basal or squamous cell carcinoma of the skin~* Known human immunodeficiency virus (HIV) or hepatitis C positivity~* Significant history of non-compliance to medical regimens or inability to grant a reliable informed consent~* More than three prior therapies~* Hepatic or renal diseases or any diseases that will obscure toxicity or alter drug metabolism~* Known active malignancies~* Active infection requiring iv antibiotics~* Systemic anticoagulants~* Enzyme-inducing antiepileptic drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues